Chugai Pharmabody Research Pte. Ltd. ('CPR') was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd (Chugai), a member of Roche group, in January 2012 and started operations on July 2, 2012. Located at Biopolis in
Singapore
, it aims to generate new antibody drugs based on Chugai's proprietary antibody engineering technologies, such as recycling antibody®, sweeping antibody®, bispecific antibody, various Fc engineered antibodies, and other new antibody engineering technologies that are under development. Position - Research Assistant in
Cell Biology and Technology Unit Job Scope: . Tool generation - expression vector construction and molecular cloning, protein expression, stable cell lines development . Drug screening - ELISA, FACS, cell-based functional assay, confocal microscopy, SDS-PAGE, Western Blotting, qPCR etc. . Cell culture - Suspension cell culture and adherent cell culture, 3D cell culture models, such as spheroid, organoid, org...